Cytokinetics (CYTK) Return on Sales (2016 - 2024)
Historic Return on Sales for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to 16.56%.
- Cytokinetics' Return on Sales rose 970500.0% to 16.56% in Q4 2024 from the same period last year, while for Dec 2024 it was 77.66%, marking a year-over-year increase of 1473100.0%. This contributed to the annual value of 15.22% for FY2024, which is 848800.0% up from last year.
- Per Cytokinetics' latest filing, its Return on Sales stood at 16.56% for Q4 2024, which was up 970500.0% from 323.39% recorded in Q3 2024.
- Over the past 5 years, Cytokinetics' Return on Sales peaked at 16.56% during Q4 2024, and registered a low of 573.91% during Q2 2024.
- Over the past 5 years, Cytokinetics' median Return on Sales value was 24.6% (recorded in 2021), while the average stood at 94.14%.
- Over the last 5 years, Cytokinetics' Return on Sales had its largest YoY gain of 970500bps in 2024, and its largest YoY loss of -4250100bps in 2024.
- Cytokinetics' Return on Sales (Quarter) stood at 3.21% in 2020, then crashed by -120bps to 0.65% in 2021, then plummeted by -10492bps to 68.52% in 2022, then dropped by -17bps to 80.49% in 2023, then skyrocketed by 121bps to 16.56% in 2024.
- Its Return on Sales stands at 16.56% for Q4 2024, versus 323.39% for Q3 2024 and 573.91% for Q2 2024.